2010 Biopharma Leads 
Pharmaceutical Technology
MAY 15, 2023
Zhejiang DTRM Biopharma and Oncore Biopharma stand in second and third positions, respectively. ‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
pharmaphorum
AUGUST 5, 2022
Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no longer viable, argues Pervaise Khan, Accenture’s UK Life Sciences Lead. And of course, all of this will feed into future treatments and positive patient outcomes – the sole purpose of pharma.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
APRIL 2, 2024
Before joining Siegfried in 2010, Wienand worked at the German specialty chemicals company Evonik Industries, Lonza highlighted. Wolfgang Wienand – leading the next chapter “Wolfgang brings a wealth of knowledge and experience to Lonza, complemented by his deep scientific and strategic expertise. billion.
Pharmaceutical Technology
MARCH 14, 2023
The company’s lead asset is NBTXR3, which is based on hafnium oxide nanoparticle that is designed to destroy tumors when activated by radiotherapy. ‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
PharmaTech
JANUARY 4, 2024
Eurofins BioPharma Product Testing (EBPT) in the US is a leading entity in the analytical testing of Cell and Gene Therapy, with its involvement dating back to 2010 at the Eurofins BPT Lancaster, PA location.
Pharmaceutical Technology
JUNE 4, 2023
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’. Encoded Therapeutics develops gene therapies for the treatment of severe genetic disorders.
Pharmaceutical Technology
MAY 15, 2023
Patent volumes related to oxazole derivatives-based cancer drug compositions Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies F. Hoffmann-La Roche is the leading patent filer of oxazole derivatives-based cancer drug compositions.
Expert insights. Personalized for you.
92 
Let's personalize your content